Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
NCIC Clinical Trials Group
OBJECTIVES: Primary * Assess the efficacy of systemic first-line treatment comprising bortezomib, cyclophosphamide, vincristine, prednisone, and rituximab, in terms of complete response rate, in patients with stage III or IV follicular non-Hodgkin's lymphoma. * Assess the incidence of severe neurotoxicity (defined as grade 3 or 4 neuropathy or neuropathic pain during the first 4 courses of treatment) in patients treated with this regimen. Secondary * Assess the overall response rate and response duration in patients treated with this regimen. * Determine progression-free and overall survival of patients treated with this regimen. * Evaluate the tolerability and characterize the toxicity profile of this regimen in these patients. * Assess quality of life, with particular focus on neurotoxicity-related changes, of patients treated with this regimen. OUTLINE: This is a multicenter, nonrandomized, open-label study. Patient receive cyclophosphamide IV over 15-45 minutes, vincristine IV over 3-5 seconds and rituximab IV over 1½-6 hours on day 1, oral prednisone daily on days 1-5, and bortezomib IV over 3-5 seconds on days 1 and 8. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at the end of each course of treatment, and on day 42 at the post treatment visit. After completion of study treatment, patients are followed at 3 and 6 weeks and then every 3-6 months thereafter. PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
